Sign up for a new account.
And get access to
The latest T1D content
Research that matters
Our daily questions
Sign up by entering your info below.
Reset Your Password
We will email you instructions to reset your
S. Rompicherla1, N. Noor1, A. Kim2, G. Nelson2, O. Odugbesan1, N. Rioles1, A. Mungmode1, J. Sarhis3, A. Roberts4, O. Osagie Ebekozien1,5, T1D Exchange Quality Improvement Collaborative Study Group
1T1D Exchange, Quality Improvement and Population Health, Boston, USA, 2The University of Tennessee Health Science Center, Memphis, USA, 3Cohen Children’s Medical Center, New York, USA, 4Seattle Children’s Hospital, Seattle, USA, 5University of Mississippi School of Population Health, Jackson, USA
Introduction: Health insurance coverage type differs significantly by socio-economic status and racial groups in the United States. There is limited data on the association between insurance and the risk of adverse outcomes for patients with pre-existing T1D and COVID19.
Objectives: The aim of this study was to determine if publicly insured pediatric and adolescent patients with Type 1 Diabetes (T1D) were more likely to experience adverse outcomes compared to privately insured patients with acute COVID-19 infections.
Methods: Data from 575 patients with previously established T1D aged <24 years with acute COVID-19 infections was analyzed from the T1DX-COVID-19 Surveillance Registry. Data for the registry was collected from 52 endocrinology clinics across the U.S, using an online survey tool. Each site completed the survey using electronic medical record (EMR) data between April 2020 and May 2021.
Increase in newly diagnosed type 1 diabetes among pediatric and adolescent patients during the COVID-19 pandemic in the United States: A multi-center analysis
This site uses Akismet to reduce spam. Learn how your comment data is processed.